Skip to main content
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. — Investor Relations & Filings

Ticker · CTMX ISIN · US23284F1057 LEI · 5493004VW2FW0QLL3345 US Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2023-03-29 Director's Dealing
Country US United States of America
Listing US CTMX

About CytomX Therapeutics, Inc.

https://cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-03-29 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes details about the equity incentive plan and shares to be issued under it. The document is not a financial report, earnings release, or management discussion, but a registration statement related to share issuance under an employee plan. This fits the category of Share Issue/Capital Change announcements, as it pertains to registering shares for issuance under an equity incentive plan. The document length is sufficient and contains substantive content about the registration, not just an announcement of a report. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2023-03-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company issued a press release announcing its full year 2022 financial results and business update, but the 8-K itself does not contain the full financial statements or detailed financial analysis. It only furnishes the press release as an exhibit. The document length is 3861 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous filings and announcements that do not fit other categories.
2023-03-27 English
10-K
Annual Report FY 2022
2023-03-27 English
10-K/A
Annual Report FY 2021
2023-03-27 English
Director's Dealing 2023
Director's Dealing
2023-03-20 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.